Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 4/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6282438 | 0.87 | AOC3 (0.73) | AOC3L3MBTL1SLC6A2SLC6A4CHRM2 | |
| SCHEMBL19742702 | 0.84 | AOC3 (0.64) | AOC3L3MBTL1SLC6A2SLC6A4CHRM2 | |
| SCHEMBL11077953 | 0.83 | AOC3 (0.68) | AOC3L3MBTL1SLC6A2SLC6A4CHRM2 | |
| SCHEMBL6743692 | 0.83 | AOC3 (0.72) | AOC3L3MBTL1SLC6A2SLC6A4CHRM2 | |
| SCHEMBL8408483 | 0.81 | AOC3 (0.56) | AOC3L3MBTL1SLC6A2SLC6A4TDP1 | |
| SCHEMBL25159738 | 0.81 | AOC3 (0.64) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL28339061 | 0.81 | AOC3 (0.64) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL3920742 | 0.81 | AOC3 (0.66) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL7784227 | 0.81 | AOC3 (0.66) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL7102577 | 0.81 | AOC3 (0.66) | AOC3L3MBTL1CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861438-B2 | Antiviral agents | PFIZER (US) | 2005-03-01 | — | — | US | claimed |
| US-6852731-B2 | Antiviral compounds | PFIZER (US) | 2005-02-08 | — | — | US | claimed |
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY | 2004-12-02 | — | — | US | claimed |
| US-20040138449-A1 | Antiviral agents | PHARMACIA & UPJOHN COMPANY | 2004-07-15 | — | — | US | claimed |
| US-6878705-B2 | 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamide antiviral agents | PFIZER (US) | 2005-04-12 | — | — | US | disclosed |
| US-6861438-B2 | Antiviral agents | PFIZER (US) | 2005-03-01 | — | — | US | disclosed |
| US-6852731-B2 | Antiviral compounds | PFIZER (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040259907-A1 | 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY | 2004-12-23 | — | — | US | disclosed |
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY | 2004-12-02 | — | — | US | disclosed |
| EP-1465895-A2 | 4-OXO-4,7-DIHYDROFURO(2,3-B)PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040138449-A1 | Antiviral agents | PHARMACIA & UPJOHN COMPANY | 2004-07-15 | — | — | US | disclosed |
| WO-2003059911-A2 | 4-OXO-4, 7-DIHYDROFURO[2,3-b]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259907-A1 | 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | IL4, ZC3HAV1, IRF3 | AOC3 3745/4885L3MBTL1 3764/4885SLC6A2 4331/4885 |
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, IRF3, IFNAR1 | AOC3 4410/4885L3MBTL1 1749/4885SLC6A2 1762/4885 |
| US-20040138449-A1 | Antiviral agents | IRF3, IFNAR1, EIF2AK2 | AOC3 4495/4885L3MBTL1 1828/4885SLC6A2 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.